Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Cablivi (caplacizumab) for the Treatment of Acquired Thrombotic Thrombocytopenic Purpura

Drug Name

Cablivi™ (caplacizumab)

Developers

Sanofi and Ablynx

Therapy Class

Bivalent anti-von Willebrand factor (-cWF) nanobody

Current Indication

Acquired thrombotic thrombocytopenic purpura

Market Sector

Haematology

Development Status

Approved in Europe
Expand

Go Top